GLP1

A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings …

A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings …

The Cureus Journal of Medical ScienceCardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic ReviewType 2 …

CureusCardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-AnalysisType 2 diabetes mellitus (T2DM) markedly increases the risk of cardiovascular and renal complications, emphasizing …

November 05, 2025 4 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email …

A large cohort study found three popular GLP-1-based diabetes drugs — semaglutide, dulaglutide, and tirzepatide — carry similar risks for serious adverse GI events, with a rate of about 12 …

People with Type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a greater reduction in risk of major adverse cardiovascular events, including heart attack, stroke …

Real-world data from over 14,000 Italian adults reveal that GLP-1 receptor agonists can induce remission in type 2 diabetes, with one clinically balanced definition linking drug use to reduced cardiovascular …

SHANGHAI, Oct 27 (Reuters) – China’s Innovent Biologics (1801.HK)opens new tabsaidopens new tabon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients …

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a …